Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?

Authors

  • Dr. Ya-Chen Tina Shih PhD,

    1. Shih is Associate Professor, Section of Health Services Research, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX
    Search for more papers by this author
  • Dr. Michael T. Halpern MD, PhD

    1. Halpern is Strategic Director, Health Services Research, American Cancer Society, Atlanta, GA
    Search for more papers by this author

  • Published online through CA First Look at http://CAonline.AmCancer.Soc.org.

  • To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

  • Disclosure: No outside financial support was provided for this manuscript, and no conflict of interest exists.

Abstract

While the past decade has seen the development of multiple new interventions to diagnose and treat cancer, as well as to improve the quality of life for cancer patients, many of these interventions have substantial costs. This has resulted in increased scrutiny of the costs of care for cancer, as well as the costs relative to the benefits for cancer treatments. It is important for oncologists and other members of the cancer community to consider and understand how economic evaluations of cancer interventions are performed and to be able to use and critique these evaluations. This review discusses the components, main types, and analytic issues of health economic evaluations using studies of cancer interventions as examples. We also highlight limitations of these economic evaluations and discuss why members of the cancer community should care about economic analyses.

Ancillary